Table 1.
Demographic and clinical characteristics by treatment cohort.
| 1st line mono-IO (n = 442) | 1st line chemo-IO (n = 915) | P-valuea | |
|---|---|---|---|
| Age at treatment start, years, median (range) | 72 (38, 85) | 68 (33, 85) | <0.001 |
| Gender, n (%) | 0.001 | ||
| Female | 251 (57) | 427 (47) | |
| Male | 191 (43) | 488 (53) | |
| Race, n (%) | 0.1 | ||
| Asian | 5 (1) | 11 (1) | |
| Black or African American | 19 (4) | 60 (7) | |
| Other | 65 (15) | 144 (16) | |
| White | 322 (73) | 610 (67) | |
| Missing | 31 (7) | 90 (10) | |
| Smoking history, n (%) | 0.004 | ||
| Yes | 418 (95) | 822 (90) | |
| No | 24 (5) | 93 (10) | |
| Practice type, n (%) | 0.3 | ||
| Academic | 31 (7) | 50 (5) | |
| Community | 411 (93) | 865 (95) | |
| Advanced stage at diagnosisb, n (%) | <0.001 | ||
| Yes | 292 (66) | 754 (82) | |
| No | 143 (32) | 150 (16) | |
| Not reported | 7 (2) | 11 (1) | |
| ECOG performance statusc, n (%) | <0.001 | ||
| 0 | 88 (20) | 251 (27) | |
| 1 | 163 (37) | 332 (36) | |
| 2+ | 107 (24) | 144 (16) | |
| Missing | 84 (19) | 188 (21) | |
| Tumor type, n (%) | 0.02 | ||
| Lung adenocarcinoma | 346 (78) | 773 (84) | |
| Lung non-small cell lung carcinoma (nsclc) (nos) | 64 (14) | 93 (10) | |
| Other | 32 (7) | 49 (5) | |
| Tissue of origin, n (%) | 0.3 | ||
| Lung | 211 (48) | 426 (47) | |
| Lymph node | 60 (14) | 125 (14) | |
| Brain | 37 (8) | 52 (6) | |
| Bone | 19 (4) | 55 (6) | |
| Other/unknown | 115 (26) | 257 (28) | |
| TMB, n (%) | <0.001 | ||
| Low (<10 mut/Mb) | 227 (51) | 583 (64) | |
| High (≥10 mut/Mb) | 215 (49) | 332 (36) | |
| PD-L1 expression, n (%) | <0.001 | ||
| No (<1% TPS) | 16 (7) | 184 (38) | |
| Low (1–49% TPS) | 33 (15) | 170 (36) | |
| High (≥50% TPS) | 174 (78) | 124 (26) | |
| Missing | 219 | 437 | |
| Total number of lines of therapy received, n (%) | 0.4 | ||
| 1 | 319 (72) | 644 (70) | |
| 2 | 85 (19) | 171 (19) | |
| 3+ | 38 (9) | 100 (11) | |
| Class of 2nd line therapy received, n (%) | <0.001 | ||
| Chemotherapy alone | 48 (39) | 78 (29) | |
| IO-Chemo combination | 23 (19) | 23 (8) | |
| Immunotherapy alone | 21 (17) | 18 (7) | |
| Other | 31 (25) | 152 (56) |
aCharacteristics were compared between cohorts using a Wilcoxon rank-sum test for continuous measures and a chi-squared test or Fisher’s exact test for categorical measures.
bIncludes stages IIIB, IIIC, IV, IVA, and IVB.
cAssessed on or up to 30 days before treatment start date.